Group items tagged

The Pharmacists' Defence Association (PDA) is probing major concerns arising from Boots' communications to pharmacists regarding the company's recently announced pension arrangements. In November, Walgreens Boots Alliance (WBA), the parent company of Boots, transferred the Boots employees' pension scheme to the financial service provider Legal and General (L&G) in a £4.8 billion deal. Boots notified staff that terms allowing an unreduced pension from age 60 have ceased immediately, following its agreement with L&G. The PDA highlighted member concerns regarding Boots management's announcement that an unreduced pension from the age of 60 is a discretionary benefit and not guaranteed under the Boots Pension Scheme (BPS), contrary to some members' assumptions.

The Pharmacists' Defence Association (PDA) has urged the community pharmacies to complete a short survey on the availability of commonly prescribed medicines. PDA is hearing from members working in community pharmacy about challenges they are facing in fulfilling prescriptions for some of the most common medicines, including antibiotics. It wants to hear from pharmacists on the front line about their recent experiences. The association said: "Whilst at this time of year the incidence of infections and illnesses can be heightened, demand is seemingly higher than usual, and we would like to hear more about how this is impacting on you and the patients in your care,"

The Professional Pharmacists Association (PDA) has demanded efforts to secure greater support and recognition for community pharmacists from governmental bodies. In its written evidence provided to the Health and Social Care select committee's pharmacy inquiry, the PDA raised concerns about the well-being of pharmacists, specifically for those who belong to minority ethnic groups and race and are subjected to bullying, harassment, and ill-treatment. The association highlighted issues in the workplace that impact pharmacists' health and well-being, including chronic understaffing, sub-standard working environments, an absence of protected training time, and experiences of racism, violence, and abuse. Parallel to the PDA's advocacy, the Royal Pharmaceutical Society (RPS) is intensifying calls for prioritising workforce wellbeing within the pharmacy domain. Stressing the pivotal role of workforce retention in addressing current challenges, RPS emphasises the need for robust support mechanisms and equitable access to mental health services.

The Pharmacists' Defence Association (PDA) has submitted evidence to the NHS Pay Review Body (PRB), emphasising on the recruitment and retention of NHS pharmacists. It has urged the PRB to help the NHS achieve two important objectives - ensuring that pharmacists can achieve well-rewarded and the service is viewed as an a ppealing alternative by student pharmacists. The PDA suggested that for the NHS to remain competitive, the PRB should focus its pay approach on employees within Bands 5-8 this year. It recognised that the last recommendation from the PRB was a "flat rate increase" and it left those working in the above-mentioned bands feeling "unhappy", which led to the CSP taking strike action over pay for the first time in their history.

The Pharmacists' Defence Association raised concerns over the practice of firing and rehiring employees, which often leads to denial of individuals' rights to redundancy, forcing them to face cuts to their terms and conditions. It noted that some employers may use the 'fire and rehire' practice to force staff to accept lower wages, different hours, or other changes in working conditions. It cited an example of a lawsuit in which Tesco lost a High Court battle when Usdaw won a case to protect workers from unfair tactics. The PDA said although the trade union won the case, the practice of firing and rehiring can still be legal in some circumstances. However, it believes the practice is both immoral and unethical.

The Pharmacists' Defence Association (PDA) is bolstering its leadership team with the appointment of Jay Badenhorst as the Director of Pharmacy, a newly created position aimed at fortifying its commitment to advancing pharmacy practice. This move comes amidst a period of significant change and challenge for frontline pharmacists, prompting the independent trade union to enhance its influence in the evolving healthcare landscape. Mr. Badenhorst, who previously served Whitworth Chemists as the Managing Director and also has leveraged his extensive knowledge of the pharmacy practice and organisational leadership as the Vice Chair of the National Pharmacy Association, reasons his "commitment to being at the forefront of positive change within the pharmacy profession." Mr. Badenhorst expressed his enthusiasm stating: "I am delighted to be joining an organisation that has so much vision, ambition and drive at a time when pharmacists have so many opportunities to develop their roles for the benefit of patients." According to Mark Koziol, Chair of PDA, the new position is a reflection of the union's commitment to pharmacy and described the new Director of Pharmacy as "a senior level, proven and award-winning pharmacy leader."

Despite being the most common genetic disorder in the UK, sickle cell disease (SCD) remains significantly underfunded and underserved compared to other genetic disorders, according to a new report published by the PDA BAME (Black, Asian and Minority Ethnic) Pharmacists' Network. The report also reveals that the disease is poorly understood within the healthcare system, including amongst pharmacists, pharmacy students, and foundation pharmacists in the UK. It emphasises the urgent need for increased awareness, funding, and improved healthcare access for SCD amongst these healthcare professionals. "A lack of education about SCD within the wider healthcare community, including pharmacy, greatly contributes to disparities in care. "Though the importance of SCD education for pharmacists and allied healthcare professionals is acknowledged, it remains unclear whether this topic is adequately addressed within the MPharm curriculum," the report said. The report further noted that in the absence of explicit guidance from the General Pharmaceutical Council (GPhC) or the Pharmaceutical Society of Northern Ireland (PSNI) and without more comprehensive education surrounding SCD embedded within the pharmacy curriculum, pharmacists and future pharmacists may remain "ill-prepared to manage patients with this complex condition." As per the report, sickle cell disease is the most prevalent genetic disorder globally, impacting millions, including around 17,000 people in England.

The BAME Pharmacists Network of the Pharmacists' Defence Association has elected three women pharmacists as it's new officials. Following the network's second set of elections since its launch in April 2020, Sima Hassan has been elected as president, Wai Chan Lau her deputy and Osariemen Egharevba-Buckman as honorary secretary. A community pharmacist for over 18 years and an academic, Ms Hassan will take over from outgoing president Elsy Gomez Campos who saw through the work of the network during a very difficult period in the midst of a global pandemic. Ms Hassan has been a prominent member of the BAME pharmacist community. She recognises and appreciates the complexities of issues that BAME pharmacists face and the scope for work that needs to done for wider recognition.

The lessons from Covid crisis applied in the future through collaboration can create a better integration between GP practices, hospitals and community pharmacies, Pharmacists Defence Association (PDA) has proposed. Stating that a more integrated healthcare system could enable pharmacists to provide effective and more efficient care to patients, the PDA proposed a model where at least two pharmacists would be working in each community pharmacy, empowered, and enabled with two-way referral pathways, having more clinical input and full access to patient records. "Such an environment could not only help to improve communications between health professionals and increase access to services for patients, but would support the NHS to operate more effectively."

Within the last few weeks, at least six pharmacists have been subjected to interim order applications - either suspended or had significant restrictions placed upon their registration pending a full 'Fitness to Practise' hearing into serious allegations being made about their prescribing practices, the Pharmacists' Defence Association (PDA) has found. It said that there has been a "dramatic increase in action being taken by the pharmacy regulator (GPhC) against pharmacist prescribers associated with certain types of online prescribing services". It has warned pharmacist prescribers who work for online pharmacies about the specific risks associated with remote prescribing using a questionnaire-based model, typically with no direct prescriber/patient interaction. Common features that underpin the allegations include the following: Overreliance on a patient questionnaire to inform clinical decision making; No patient/prescriber interaction; Prescribing high risk medicines without adequate safeguards; Inadequate systems and processes leading to inappropriate prescribing; Very high volumes of prescriptions being authorised in short periods of time; and Prescribers/patient relationship established via an unregulated online portal.

Too many unreasonable demands placed on pharmacists by employers affect their health and wellbeing at work, a stress and wellbeing survey conducted by The Pharmacists' Defence Association (PDA) Union revealed. The survey, conducted during Autumn 2021, covered views of over 2,000 pharmacists employed by big multiples - Lloyds, Boots, and Well. This survey used questions developed by the Health and Safety Executive (HSE), which enabled the union to understand more about stress and wellbeing in three of the largest community pharmacy multiples. Analysing the survey, the PDA said that some pharmacists working for each of the three employers highlighted "unachievable targets, unrealistic time pressures, and most worrying of all reported numerous instances of bullying and harassment." An overwhelming majority of the respondents reflected personal sacrifices made by the pharmacists to ensure patient services are not impacted by the poor conditions and environments in some pharmacies.

The Pharmacists' Defence Association (PDA) has created a form to help locum and other pharmacists to report about breach of NHS contract by community pharmacy. According to the association, they have been told by increasing number of pharmacists about contractors closing pharmacies, despite a locum readily available to cover the shift. The PDA said this is an issue of NHS contractual breach and creates difficulties for patients, and so they have created the form to assist members to report unnecessary closures to the relevant NHS England & Improvement pharmacy contract team. A locum pharmacist, who does not wish to be named, has alleged that a community pharmacy declined their offer to cover an extra shift for £5 more per hour, and decided to close the store, denying the public access to services. The pharmacist recalled the occasion while writing in the PDA's latest member voice article.

The Pharmacists' Defence Association (PDA) has welcomed the Chancellor's announcement of a 5.5 percent pay increase for NHS pharmacists. Following the acceptance of the NHS Pay Review Body's (PRB) recommendations, Chancellor Rachel Reeves shared the announcement in a speech to Parliament on 29 July. She confirmed that the pay review bodies' recommendations for health and education for 2024-25 would be fully implemented. Reeves' speech came alongside the release of her audit into public finances, a commitment she made shortly after the recent election. The audit confirms that the recommendations from various PRBs, including those for NHS staff, doctors, dentists, teachers, and other public servants, have been approved and will be acted upon. "That is the right decision for the people who work in and most importantly the people who use our public services…giving hardworking staff the pay rise they deserve while ensuring we can recruit and retain the people we need," Reeves announced.

Boots and the Pharmacists' Defence Association (PDA) Union have released a joint statement to confirm that there will be a pay increase for trainee pharmacists in England and Northern Ireland from April 2024. From 1 April 2024, the new hourly pay rate for trainee pharmacists working at Boots pharmacies will be £12.69 for Zone A in England/Northern Ireland, £13.79 for Zone B in England and £14.05 for Zone C in England. "This increase will be applied centrally in the April pay run," said the statement from the Boots and the PDA Union. Team members can see the new rate of pay in the Benefits Box during the annual enrolment window from 20 February 2024, it added. In August 2023, pay for trainee pharmacists at Boots in England and Northern Ireland was increased to £11.64 per hour for Zone A, £12.77 per hour for Zone B and £12.88 per hour for Zone C.

Pharmacists, along with workers from other public sector workplaces, marched on 8 September demanding that the Scottish government take all available action to mitigate the biggest reduction in living standards workers will have experienced for generations. Pharmacists Defence' Association (PDA) members participated in the Scottish Trade Unions Congress (STUC) march to let the government know that "Scotland demands better". Paul Flynn, PDA national officer, said: "Pharmacists will be unwelcomely familiar with diminished purchasing power and a squeeze on household budgets for patients, colleagues and pharmacists but what we will see this year and into 2023 will make previous experience pale by comparison." The march organised by STUC saw thousands of workers, activists and concerned individuals march through the centre of Edinburgh's Historic Old Town in good spirits while bearing flags and banners, chanting, singing, and calling for change in Scotland.

The Pharmacists' Defence Association (PDA) has called on pharmacy employers and pharmacists organisations to make donations towards the Pharmacist Support charity in the new year. The association has urged them to donate £1 per pharmacist employee or member to the charity group to increase its funding from 2022 onwards. Pharmacist Support, an independent charity, provides a variety of support services to pharmacists and their families, former pharmacists and pharmacy students in Great Britain. It provides support through twelve sessions of fully funded counselling topharmacists, students, or trainees. Since 2018, the association has donated more than £150,000 to the charity, in turn supporting its members who additionally seek assistance from Pharmacist Support.

The Royal Pharmaceutical Society (RPS) and the Pharmacists' Defence Association (PDA) have responded to the Department of Health and Social Care (DHSC) consultation on pharmacy supervision, which was launched in early December last year. The DSHC set out proposals to amend the Medicines Act 1968 and The Human Medicines Regulations 2012 to allow registered pharmacy technicians to work without direct supervision, which in turn will help free up pharmacists to provide more clinical care and reduce GP appointments. While the RPS supported the legislative change, it highlighted a range of topics that should be considered and clarified in regulations and guidance. According to RPS, the new concept of 'authorisation', including around documentation, accountability, and the role of superintendent pharmacist and responsible pharmacist, needs clarification.

The Pharmacists' Defence Association (PDA) has written to the National Pharmacy Association (NPA) to highlight several important points regarding their proposed "day of action" on 20 June 2024. The NPA describes this initiative as a response to the "emergency across the community pharmacy sector." In a letter addressed to NPA Chair Nick Kaye and Chief Executive Paul Rees, the PDA's director of pharmacy, Jay Badenhorst stressed the need for NPA members to consider their obligations to staff and patients before participating in the planned actions. He stated, "We are supportive of a new contractual framework for the community pharmacy sector." "However, any actions taken must ensure the safety of patients and the operational integrity of pharmacies." The PDA's letter also expressed concerns over the safety and operational impact of the proposed symbolic gestures, including turning off lights and blacking out windows.

The Pharmacists' Defence Association (PDA) has urged pharmacists working in Covid-19 vaccination role to report any concerns about the needles and syringes supplied with the Moderna Spikevax Bivalent vaccine. The association has heard reports of bending when vaccinators pierce the top of the vial containing the Covid-19 vaccine doses, needles falling out during manipulation and appearing to be bent even before removal from the packaging. PDA has advised its members who are working in a Covid-19 vaccination role "to report any concerns via the Yellow Card medical device reporting system, and to keep up to date with NHS clinical updates for ongoing information and guidance." Current advice from the NHS includes sharing of video and poster resources (available on FutureNHS) which have been produced by the supplier to support the introduction of the new administration needles and syringes for Spikevax Bivalent. This is following a switch from BD Flu+ 23G x 25mm 1ml syringe combined needle and syringe (CNS) to the Owen Mumford Unifine Safety Retractable Needle 25G x 25mm & 1ml Syringe.

"Discussions must involve the government on behalf of NHS Scotland, CPS on behalf of the owners, and the PDA as the pharmacists' representative," it said. The association believes that there is a need for discussion and decision-making that listens to and balances the rights and responsibilities of both employers and workers, to generate benefits for individuals, organisations, and society. It added: "Even though Scotland provides the most generous community pharmacy settlement in the UK, recent reports suggest it is not enough for pharmacy owners with CPS's rejection of the latest funding proposal in May. Though the Scottish government found an extra £20M to ease pressures related to medicines price increases, an overall agreement has still not been reached." "The UK-wide chains may be doing less well in the parts of their networks covered by the Westminster government's contract, but the taxpayers and government of Scotland need to be given reassurance that they are in no way subsidising funding shortfalls in England's pharmacy contract." Recently, when LloydsPharmacy's Scotland branches recently came on the market, they appear to have been sold exclusively to existing contractors, including the UK-wide multiple, Rowlands Pharmacy, who have acquired 30 of them. Other small and medium-sized Scottish pharmacy chains have apparently been able to double in size overnight by acquiring branches.